SERA - NASDAQ
Sera Prognostics, Inc.
$2.22
+8.3%Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
At a Glance
Live SnapshotSera Prognostics, Inc. Management Team
Mr. Lee Anderson
Chief Commercial Officer
Dr. Paul Kearney Ph.D.
Chief Data Officer
Compensation
$468,734
Mr. Austin Aerts
Chief Financial Officer
Compensation
$367,625
Mr. Robert G. Harrison
Chief Information Officer
Compensation
$384,178
Dr. John J. Boniface Ph.D.
Chief Scientific Officer
Compensation
$431,282
Dr. Gregory C. Critchfield M.D., M.S.
Executive Director
Compensation
$19,904
Mr. Benjamin G. Jackson J.D.
General Counsel
Compensation
$410,755
Ms. Evguenia Lindgardt M.B.A.
President, Chief Executive Officer & Director
Compensation
$693,398
Sera Prognostics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $160K and sold $842K worth of SERA shares, resulting in $682K of net selling activity.
3 Months
0
0.00
51.1K
99.17K
-99K
-$99K
3-6 Months
0
0.00
50.1K
153.11K
-153K
-$153K
6-9 Months
0
0.00
129.6K
376.06K
-376K
-$376K
9-12 Months
100.0K
160.00K
96.6K
213.65K
-54K
-$54K
Top Buyers
Kamdar Kim P.
Director
$40K
Critchfield Gregory C
Director
$40K
Phillips Joshua
Director
$40K
Mirza Mansoor Raza
Director
$40K
Top Sellers
Lindgardt Zhenya
Director, Officer: Chief Executive Officer
$315K
Kearney Paul
Officer: Chief Data Officer
$195K
Harrison Robert Gardner
Officer: Chief Information Officer
$100K
Aerts Austin
Officer: Chief Financial Officer
$94K
Boniface John J.
Officer: Chief Scientific Officer
$58K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $682K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 4 buyers. More insiders selling than buying suggests cautious or negative sentiment.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
SERA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | April 23, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 23, 2025 | June 05, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 23, 2024 | June 06, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 25, 2023 | June 08, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 22, 2022 | June 03, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.